Atrial fibrillation patients with hypertrophic cardiomyopathy: Do we need new stroke risk stratification?

Due to very high thromboembolic risk, life-long oral anticoagulation is recommended in all hypertrophic cardiomyopathy (HCM) patients with non-valvular atrial fibrillation (NVAF).1-3 We read with great interest the paper by Tsuda et al.4 who rightly emphasized the importance of HCM on thromboembolism in patients with AF.
Source: Heart Rhythm - Category: Cardiology Authors: Source Type: research